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Introduction: Despite signiﬁcant advances in vascular biology, bioengineering, and pharmacology, restenosis remains
a limitation to the overall efﬁcacy of vascular reconstructions, both percutaneous and open. Although the pathophysi-
ology of intimal hyperplasia is complex, a number of drugs and molecular tools have been identiﬁed that can prevent
restenosis. Moreover, the focal nature of this process lends itself to treatment with local drug administration. This article
provides a broad overview of current and future techniques for local drug delivery that have been developed to prevent
restenosis after vascular interventions.
Methods: A systematic electronic literature search using PubMed was performed for all accessible published articles
through September 2012. In an effort to remain current, additional searches were performed for abstracts presented at
relevant societal meetings, ﬁled patents, clinical trials, and funded National Institutes of Health awards.
Results: The efﬁcacy of local drug delivery has been demonstrated in the coronary circulation with the current clinical
use of drug-eluting stents. Until recently, however, drug-eluting stents were not found to be efﬁcacious in the
peripheral circulation. Further pursuit of intraluminal devices has led to the development of balloon-based technolo-
gies, with a recent surge in trials involving drug-eluting balloons. Early data appear encouraging, particularly for
treatment of superﬁcial femoral artery lesions, and several devices have recently received the Conformité Européene
mark in Europe. Investigators have also explored the periadventitial application of biomaterials containing anti-
restenotic drugs, an approach that could be particularly useful for surgical bypass or endarterectomy. In the past,
systemic drug delivery has been unsuccessful; however, there has been recent exploration of intravenous delivery of
drugs designed speciﬁcally to target injured or reconstructed arteries. Our review revealed a multitude of additional
interesting strategies, including >65 new patents issued during the past 2 years for approaches to local drug delivery
focused on preventing restenosis.
Conclusions: Restenosis after intraluminal or open vascular reconstruction remains an important clinical problem. Success
in the coronary circulation has not translated into solutions for the peripheral arteries. However, our literature review
reveals a number of promising approaches, including drug-eluting balloons, periadventitial drug delivery, and targeted
systemic therapies. These and other innovations suggest that the future is bright and that a solution for preventing
restenosis in peripheral vessels will soon be at hand. (J Vasc Surg 2013;57:1403-14.)Without exception, all interventions designed to treat
atherosclerotic occlusive disease are complicated by reste-
nosis. The development of recurrent restenotic disease
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sis severely limits the overall efﬁcacy of these interventions
and can occur in up to 80% of patients.1 The process
involves a complex cascade of reactions that result in
luminal narrowing through a combination of neointimal
hyperplasia and constrictive remodeling. Despite many
advances in the ﬁelds of vascular biology, pharmacol-
ogy, and bioengineering, restenosis remains a signiﬁcant
problem.2,3
The use of systemic drug therapy to prevent restenosis
was ﬁrst seriously investigated in the late 1970s. Despite
years of study, many of the compounds that have been
evaluated are poorly tolerated, have narrow therapeutic
ranges, and have diminished efﬁcacy when administered
systemically.4,5 These outcomes have led to the concept
of local drug delivery (LDD), where high doses of a thera-
peutic agent are administered directly to a treated artery or
vein without engendering adverse systemic effects. LDD
can result in drug concentrations in vascular tissues that
are 400 to 1000 times higher than that achieved after
systemic administration of the same compound.6-9 The1403
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vessel wall is an attractive strategy that is likely to be effec-
tive if several conditions can be met:
1. There is steady delivery of the drug over time;
2. Effective drug concentrations can be maintained;
3. There is absence of local or systemic toxicity; and
importantly,
4. Themechanism of delivery does not incite restenosis.10
Fortunately, restenosis lends itself to treatment by
LDD because it is often a focal process.
Consequently, during the past 2 decades, there has
been an explosion of interest by clinicians, scientists, and
medical device manufacturers to develop devices or bioma-
terials, or both, that locally release drugs that can prevent
restenosis. We have focused on technologies that prevent
restenosis in the peripheral circulation. However, mention
of the coronary vasculature is relevant in many sections
because of the historical signiﬁcance, such as drug-eluting
stents (DESs). Moreover, some technology to date has
only been evaluated in the coronary circulation, with the
presumption that at some point it will be translated to
the periphery. We have attempted to provide a comprehen-
sive overview of the available options to prevent restenosis,
including innovations that have been tested only in animals
as well as those that have been recently approved for clinical
use.
INTRALUMINAL DRUG-DELIVERY DEVICES
Drug-eluting stents. DESs are routinely used to treat
coronary artery disease, with the ﬁrst generation of these
devices approved by the U.S. Food and Drug Administra-
tion (FDA) in 2003. DESs over the short term produce
a signiﬁcant reduction in intimal hyperplasia or restenosis
compared with bare-metal stents (BMSs).11 In a meta-
analysis, Settler et al12 found a noticeable reduction in
target lesion revascularization (TLR) rates, deﬁned as
a repeat percutaneous intervention or bypass surgery of the
target lesion because of restenosis or other complications.
Sirolimus and paclitaxel DESs produced signiﬁcant reduc-
tions in TLR of 30% and 42%, respectively, when individ-
ually compared with BMSs.12 Further analysis revealed that
the sirolimus DES had a more robust reduction in TLR
than the paclitaxel DES.12 Currently, Abbott, Boston
Scientiﬁc, and Medtronic all market FDA-approved DESs.
Despite their ready adoption into clinical use, DESs
have a number of limitations, as detailed in Table I. Prime
among these is the potential for the DES to produce late
in-stent thrombosis resulting in the need for dual-
antiplatelet therapy. In January 2007, the FDA advised
that DESs are associated with a small but signiﬁcant
increase in early stent thrombosis compared with BMSs;
the clinical consequence of stent thrombosis can be devas-
tating. There is a lack of re-endothelialization related to
inhibition of endothelial cell proliferation and migration
because the drug is delivered to the luminal surface.
Another limitation of DESs is that drug delivery to thevessel wall is not uniform, with most of the drug concen-
trated at the struts of the stent. Moreover, stents have
also been shown to incite intimal hyperplasia because of
increased trauma to the vessel wall. Although metallic
stents prevent the elastic recoil that can develop after
balloon angioplasty, the trauma they produce can incite
an intense inﬂammatory reaction that leads to in-stent
restenosis; the degree of restenosis is greater than that
produced by conventional balloon angioplasty.5 Lastly
and importantly, DESs are costly, a factor that is becoming
more relevant in an era of constrained health care
resources.
Despite the initial success of DESs in the coronary
arteries, the effectiveness of this technology in the periph-
eral circulation has only recently become evident. The
Sirolimus-Coated Cordis SMART Nitinol Self-Expanding
Stent for the Treatment of Obstructing Superﬁcial Femoral
Artery Disease (SIROCCO) trials (Cordis Corp, Hialeah,
Fla) were randomized, double-blinded studies designed
to assess the efﬁcacy of a sirolimus DES for the treatment
of superﬁcial femoral artery (SFA) lesions.13 The Superﬁcial
Femoral Artery Treatment with Drug-Eluting Stents
(STRIDES) trial (Abbott Vascular; Abbott Park, Ill) evalu-
ated a novel everolimus DES designed with a high drug
load and longer elution proﬁle for the treatment of SFA
and popliteal lesions.14 In both of these trials, however,
there was no signiﬁcant difference in the outcomes of
DESs vs BMSs.
Recently, Cook Medical (Bloomington, Ind) reported
more favorable outcomes in a randomized, controlled,
multinational trial in which its Zilver PTX polymer-free
paclitaxel-eluting nitinol DES was compared with standard
angioplasty for femoropopliteal lesions. A total of 479
patients were enrolled from the U.S., Japan, and Germany.
At 12 months, the primary patency for patients receiving
the DES was 81.2% compared with 32.8% for standard
angioplasty.15 Patients receiving the primary DES also
exhibited superior 12-month event-free survival (90.4% vs
82.6%). As an evolution of this trial, the DES was
compared with the BMS after angioplasty failure. In this
secondary evaluation, the Zilver DES also exhibited supe-
rior primary patency (89.9% vs 73.0%) and clinical beneﬁt
(90.5% vs 72.3%) compared with the BMS.15 As a result
of these ﬁndings, the FDA very recently approved the Zil-
ver PTX device for use in treating femoropopliteal lesions.
The Drug-Eluting Stents in the Critically Ischemic
Lower Leg (DESTINY) trial was a randomized, multi-
center study in which the efﬁcacy of the Xience Prime
everolimus-DES (Abbott Vascular) was compared with
a BMS in patients with infrapopliteal lesions. Results at
12 months demonstrated signiﬁcantly improved patency
rates with use of the everolimus DES than with the BMS
(85.2% vs 54.4%). The Yukon-Drug-Eluting Stent Below
The Knee (YUKON-BTK) is a randomized, double-
blinded study of a polymer-free sirolimus DES (Yukon,
Translumina, Munich, Germany) vs a BMS. The primary
patency rate at 1 year was 80.6% in patients receiving the
sirolimus DES compared with 55.6% in patients receiving
Table I. Intraluminal drug delivery devices
Intraluminal
devices Advantages Disadvantages Current status
Representative
publications
Author (year)
Drug-eluting
stent
d Reduced incidence of
restenosis
d Effectively prevents reste-
nosis in coronary vessels
d Safe
d Lack of systemic toxicity
d Prevents sub-acute recoil
d Poor results in peripheral
arteries
d Hypersensitivity reactions
d Costly
d Incomplete
reendothelialization
d Late stent thrombosis
d Lifelong antiplatelet
therapy
d Localized aneurysms
d Drug delivery not uniform
d Limited drug delivery due
to small surface area of
stent
Currently in clinical
use in the coronary
circulation
Bosiers et al37 (2008)
Herdeg et al38 (2008)
Tepe et al23 (2008)
Sharma et al5 (2011)
Gertz et al10 (2010)
Dual drug-eluting
stent
d Can release both antiproli-
ferative and antithrom-
botic drugs (at different
rates)
d Reduction in restenosis
d Antirestenotic efﬁcacy
seen at long-term follow-
up at 2 years
d Same as single-drug stents Currently in clinical
trials
Krucoff et al39 (2008)
Huang et al40 (2010)
Drug-eluting
balloon
d Homogeneous drug
delivery to vessel wall
d Limited need for antiplate-
let therapy
d No stent thrombosis
d No stent scaffolding to
disrupt patterns of ﬂow
d Can be used in very small
vessels
d Immediate drug release
d Simultaneous plaque
compression and drug
delivery
d No residual foreign body
d Not as effective as DES
in coronary vessels
d Elastic recoil
d Negative remodeling
d Cost
d One-time use
Currently in clinical
trials
Brieger et al25 (1997)
Werk et al24 (2008)
Tepe et al23 (2008)
Boisers (2008)
De Labriolle et al34 (2009)
Porous balloon d More effective drugdelivery
through a balloon
d Vascular barotrauma due
to jetting
d Holes can become
obstructed leading to
nonhomogeneous drug
delivery
d Systemic release of drug
Currently in clinical
trials
Lambert et al26 (1993)
Brieger et al25 (1997)
DES, Drug-eluting stent.
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DES group compared with 17.5% in the BMS group,
this ﬁnding did not achieve statistical signiﬁcance. In
trials involving infrapopliteal disease, patients treated
were almost exclusively those with limb-threatening
ischemia.
Many clinical trials are currently under way to determine
the efﬁcacy ofDES for the treatment of infrainguinal disease.
Ongoing trials include Percutaneous Transluminal Angio-
plasty And Drug Eluting Stents For Infrapopliteal Lesions
In Critical Limb Ischemia (PADI), a randomized,controlled trial comparing a paclitaxel DES vs standard
angioplasty; Comparing Angioplasty and DES in the Treat-
ment of Subjects With Ischemic Infrapopliteal Arterial
Disease (ACHILLES) a randomized, controlled trial
comparing a sirolimus DES vs standard angioplasty, as well
as others. Thus, encouraging data have emerged regarding
the use of DESs for the peripheral circulation (Table II).
The trials thus far have been small and restrictive with regard
to TransAtlantic Inter-Society Consensus lesions. Further
evaluation will be necessary to determine the role of DESs
in the full spectrum of infrainguinal pathology.
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DES. The rationale for the development of the dual DES
is to allow a combination of drugs, the effect of which
might be additive or synergistic, to be delivered from the
same stent. Although preclinical studies with this tech-
nology have been encouraging, clinical studies with dual
DESs have not demonstrated beneﬁt.
Another innovation has been the development of the
covered stent. Although these are not DESs, they were
developed with the goal of providing a physical barrier to
ingrowth of intimal hyperplasia into the treated artery.
Unfortunately, covered stents have not provided a signiﬁ-
cant advance beyond outcomes of BMSs.
Bioresorbable stents. Bioresorbable stents are de-
signed to provide temporary architectural support for the
vessel wall but are fully biodegradable. They may or may
not elute drugs. The hypothetical advantages of biodegrad-
able stents are several. The absence of a permanent foreign
body might diminish the inﬂammatory response of the arte-
rial wall to stent implantation and diminish restenosis. More-
over, the absence of a permanent rigid metal object ﬁxed in
the arterial wall might allow the vessel to maintain its normal
physiologic vasomotor tone.16 Also, in the absence of
a permanent metal implant, the potential for reinterventions
might be enhanced. Reintervention in a conventionally
stented artery is difﬁcult because of the inability to dilate the
artery beyond the original size of the stent. Moreover, if
a surgical bypass is subsequently required, vessels treatedwith
metal stents cannot be clamped or used for an anastomosis;
these issues are resolved by bioresorbable stents. Lastly,
bioresorbable stents can be used in pediatric patients where
vessels need to grow or in patients with metal allergies.16,17
Bioresorbable stents have been constructed from poly-
mer and metallic alloys. The initial polymer-based bio-
resorbable stents were tested in animals and produced
marked inﬂammation that resulted in enhanced intimal
hyperplasia and thrombosis.16 Lincoff et al,18 however,
demonstrated in a porcine model that stents composed of
poly-L-lactide (PLLA) produced minimal inﬂammation
and durable results. Yamawaki et al19 combined a tyrosine
kinase inhibitor that blocked proliferation with a bio-
degradable stent made of PLLA and found a diminution
in restenosis. PLLA degrades over a 2-year period after
implantation. There is a decrease in radial support at w6
months, loss of mass starting at 12 months, and complete
resorption by 24 months.19
The A Bioabsorbable Everolimus-Eluting Coronary
Stent System (ABSORB) trial (Abbott Vascular) was
a prospective but uncontrolled multicenter study to assess
the efﬁcacy of an everolimus-eluting bioresorbable stent
with a polylactic acid backbone.20 Thirty patients with
single de novo coronary lesions were treated, and at 2 years
postimplantation, the stents had completely resorbed and
the rate of restenosis was 0%.20 At the 4-year follow-up,
there was no stent thrombosis or closure. In 2011, Abbott
initiated the ABSORB II trial, which is a randomized,
controlled, multicenter study comparing the Absorb bio-
resorbable vascular scaffolding with its Xience Primeeverolimus DES for the treatment of coronary lesions.
The study is under way, and the investigators aim to recruit
w500 patients at 40 sites. The Absorb bioresorbable scaf-
fold has received the Conformité Européene mark and is
currently available at select European centers.
Bioresorbable alloy stents, most commonly composed
of magnesium, have been used in animals and clinically.
Magnesium has been the chosen alloy because it is an
essential mineral well tolerated by the body and absorbs
over 4 months. Metallic bioresorbable stents have speciﬁc
advantages over polymer-based analogs, including in-
creased strength, more rapid degradation, complete radio-
pacity, and importantly, metal alloys produce only
a minimal inﬂammatory response. The Clinical Perfor-
mance and Angiographic Results of Coronary Stenting
with Absorbable Metal Stents (PROGRESS-AMS) trial
was a prospective multicenter controlled but nonrandom-
ized study intended to evaluate the treatment of a single
de novo coronary lesion using a magnesium bioresorbable
stent containing a calcium antagonist. Intravascular ultra-
sound assessment revealed that stents were completely
absorbed by the vessel wall at 4 months; however, rates
of restenosis at 4 months were identical for the magnesium
alloy and the BMS (w38% for both).17 Although this stent
failed to show superiority over the BMS in this limited
trial, the biocompatibility of the alloy in humans was
demonstrated.
Thus, clinical evaluation of bioresorbable stent tech-
nology is ongoing. However, larger randomized controlled
trials are necessary to truly assess efﬁcacy. Further investiga-
tion is needed to verify that this technology is indeed an
advance over DESs or drug-eluting balloons (DEBs). At
this point, these stents have not been evaluated in the
peripheral circulation, although an evaluation of the
Remedy PLLA stent (Kyoto Medical, Kyoto, Japan) in
the superﬁcial femoral artery is currently under way.
Drug-eluting balloon. Initially developed in the
1980s, DEBs have recently had a resurgence as investiga-
tors search for ways to overcome the limitations of DESs.
A limitation of DESs is the inconsistency of drug delivery;
speciﬁcally, a stent contacts only 15% of the vessel wall and
this small area is where drug elution occurs.21 Using
a balloon to deliver drug to the arterial wall allows for
uniform delivery, with nearly complete and homogeneous
coating of the surface of the lesion. Further limitations of
DESs include the need for long lengths to cover the entire
surface of a diseased vessel. Moreover, stents are associated
with excessive intimal hyperplasia and do not allow for
adaptive remodeling. Restenotic or thrombosed stents are
difﬁcult to reopen. Lastly, stents are costly compared with
conventional balloon angioplasty. Although the initial cost
of DEBs will be high, this is likely to diminish over time
relative to stents.
The quest for pharmacologic platforms that are not
based on stents has steered clinical investigators and device
manufacturers toward the development of DEBs. These
devices consist of an angioplasty balloon coated with a poly-
mer that elutes an antiproliferative agent and are designed
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deliver a drug to prevent restenosis. Interestingly, almost
all trials of DEBs have used paclitaxel, a drug that inhibits
microtubule assembly and selectively inhibits smooth
muscle proliferation, migration, and extracellular matrix
deposition.22 Paclitaxel is well suited for delivery by
a DEB because it is highly lipophilic, allowing rapid intra-
cellular uptake after a brief administration. To date, there
appears to have been minimal success with DEBs and
rapamycin.
Older methods of balloon-eluting drug delivery failed
to achieve clinical success because of poor retention of
drug at the site of injury. However, newer technologies
have been developed in recent years, with balloons
composed of polymers that allow enhanced drug loading
and improved controlled release into the vessel wall. Many
of the currently available balloons use an organic substrate
or an excipient, such as urea or iopromide, that helps attach
paclitaxel to the balloon and allows for a more uniform
distribution of the drug into the arterial wall.
There has been a surge in clinical trials investigating the
use of DEB technologies for treatment of infrainguinal
disease. One of the earliest was the Local Taxane with Short
Exposure for Reduction of Restenosis in Distal Arteries
(THUNDER), a multicenter, randomized, controlled trial
for the treatment of femoropopliteal disease comparing
a paclitaxel-eluting balloon (Bavaria Medizin Technologie
GmbH, Germany; 3 mg paclitaxel/mm2 of balloon surface)
with an uncoated balloon.23 Lesions treated with the
paclitaxel-eluting balloon had reduced late lumen loss
(LLL) compared with the control and a reduced TLR rate
at 6 and 24 months’ follow-up. The Femoral Paclitaxel
(FemPac) study was another multicenter, randomized,
controlled trial investigating the safety and efﬁcacy of
DEBs for the treatment of femoropopliteal disease. This trial
compared the use of a paclitaxel-eluting balloon (Bavaria
Medizin Technologie GmbH; 3 mg paclitaxel/mm2 of
balloon surface) with an uncoated balloon. Investigators re-
ported a statistically signiﬁcant lower LLL and TLR rate at 6
months in the DEB group and clinical improvement as evi-
denced by an improved Rutherford class.24
Lutonix Paclitaxel-Coated Balloon for the Prevention of
Femoropoliteal Restenosis (LEVANT I) was a randomized
trial designed to evaluate the use of a paclitaxel-eluting
balloon (Moxy, New Hope, Minn; 2 mg/mm2 paclitaxel/
mm2 of balloon surface) compared with an uncoated
balloon, with and without stenting, for the treatment of
femoropopliteal disease. The DEB used in this study has
a proprietary hydrophilic, nonpolymeric carrier molecule
that facilitates rapid drug transfer upon inﬂation. Investiga-
tors enrolled 101 patients to receive a DEB (n ¼ 37), an
uncoated balloon (n ¼ 38), or stenting (n ¼ 26). Patients
in the stent group were treated with DEB (n ¼ 12) or an
uncoated (n ¼ 14) balloon before stenting. Patients who
received the DEB had a lower LLL at 6 months, although
the TLR rate was not signiﬁcantly diminished. Subgroup
analysis found a similar LLL for patients receiving DEB
and DEB plus stent. As a result of the success of this trial,the sponsors have initiated the LEVANT II trial to assess
primary patency at 12 months. Recently presented was
Paclitaxel Coated Balloons in Femoral Indication to Defeat
Restenosis (PACIFIER), a randomized controlled trial
evaluating the use of a paclitaxel-eluting balloon for the
treatment of femoropopliteal disease in 91 patients. Investi-
gators in this trial reported an extraordinarily low LLL and
TLR at 6 months for DEBs.
A number of studies are ongoing. Preliminary data
from a multicenter Italian registry revealed high patency
rates for the DEB IN.PACT Amphirion (Medtronic, Min-
neapolis, Minn) and improved clinical outcomes at 1 year
compared with historic controls of primary angioplasty.
Medtronic has invested heavily in its IN.PACT DEB and
has initiated several single and multicenter trials worldwide.
The IN.PACT SFA (IN.PACT Admiral Drug-Eluting
Balloon vs. Standard Balloon Angioplasty for the Treat-
ment of Superﬁcial Femoral Arterial [SFA] and Proximal
Popliteal Arterial [PPA] disease) I & II will evaluate the
efﬁcacy of the IN.PACT Admiral DEB for femoropopliteal
lesions. DEBATE-BTK (Drug Eluting Balloon in
peripherAl inTErvention For Below The Knee
Angioplasty Evaluation), IN.PACT DEEP (IN.PACT
Amphirion Drug Eluting Balloon vs Standard PTA for
the Treatment of Below the Knee Critical Limb Ischemia),
and PICCOLO (Paclitaxel-Coated Balloons for Prevention
of Restenosis) are all comparing the IN.PACT Amphirion
paclitaxel-eluting balloon vs a noneluting balloon for
below-the-knee vascular lesions. These trials will be impor-
tant to determine the efﬁciency of DEBs for distal lesions.
The Drug Eluting Balloon Evaluation for Lower Limb
mUltilevel treatMent (DEBELLUM) trial, which is also
currently under way, will evaluate the same DEB,
IN.PACT Amphirion, for treatment of all infrainguinal
disease. A comprehensive list of completed and ongoing
trials is included in Table III.
Currently, all aforementioned DEBs have received the
Conformité Européene mark, and the data for this tech-
nology are highly encouraging. Thus far, these trials have
proven the safety and efﬁcacy of DEB, but larger and
better-controlled trials are necessary with longer-term
follow-up. Nevertheless, many of the large medical device
manufacturers have sensed signiﬁcant potential and have
embraced DEBs. There is little doubt that this technology
will play a signiﬁcant role in vascular treatments in the
future.
Porous and microporous balloons. As balloon tech-
nology has evolved, investigators continue to search for
a more efﬁcient means to locally deliver a drug using the
balloon as a platform. A variant of the DEB is the porous
balloon. Rather than coating the balloon with a drug, the
agent to be applied is contained within the balloon and
released through pores when the balloon is inﬂated. As
with more conventional DEBs, these devices have the
ability to conform to the shape of a vessel, allowing
complete and circumferential drug delivery.
Two approaches have been reported. The ﬁrst involves
initial angioplasty with a conventional balloon, followed
Table II. Trials evaluating drug-eluting stents
Trial
name/author Vascular territory Status Study period Drug; stent
SIROCCO SFA Published Feb 2001-Jun 2003 Sirolimus; Cordis SMART
STRIDES SFA/POP Published May 2007-Jul 2008 Everolimus; Dynalink-E
Zilver PTX SFA/POP Published Mar 2005-Oct 2009 Paclitaxel; Zilver PTX
DESTINY Infra-POP Published Mar 2008-Nov 2010 Everolimus; Xience V
Yukon BTK Infra-POP Published Apr 2006-Mar 2010 Sirolimus; Yukon-BTX
ACHILLES BTK Presented at LINC 2011 Mar 2008-Jan 2011 Sirolimus; Cypher Select
SiroBTK Infra-POP Published Jun 2002-Sep 2005 Sirolimus; Cypher
PADI trial Infra-POP Ongoing Aug 2007-Dec 2012 Paclitaxel; Taxus
DESTINY 2 BTK Ongoing Jul 2011-Jul 2013 Everolimus; Xience Prime
Promus BTK BTK Not yet enrolling Aug 2012-Aug 2014 Everolimus; Promus Element
PES-BTK-70 BTK Ongoing Jan 2012-Oct 2012 Paclitaxel; nitinol self-expanding
stent
BMS, Bare-metal stent; BTK, below the knee; DEB, drug-eluting balloon; DES, drug-eluting stent; DESTINY, Drug-Eluting Stents in the Critically Ischemic
Lower Leg; LINC, Leipzig Interventional Course; NA, not available; NR, not reported; PADI, Percutaneous Transluminal Angioplasty And Drug Eluting
Stents For Infrapopliteal Lesions In Critical Limb Ischemia; PES-BTK-70, Paclitaxel-Eluting Stent to Treat Below The Knee Arteries; POP, popliteal; PTA,
percutaneous transluminal angioplasty; SFA, superﬁcial femoral artery; SIROCCO, Sirolimus-Coated Cordis Self-expandable Stent; STRIDES, Superﬁcial
Femoral Artery Treatment with Drug-Eluting Stents; TLR, target lesion revascularization.
Cypher Select, Cordis Corp. Hialeah, Fla.
Dynalink-E, Abbott Vascular, Abbott Park, Ill.
Promus Element, Boston Scientiﬁc, Natick, Mass.
SMART, Cordis Corp, Hialeah, Fla.
Xience, Abbott Vascular, Abbott Park, Ill.
Yukon, Translumina, Munich, Germany.
Zilver, Cook Medical, Bloomington, Ind.
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The alternative method involves concurrent drug infusion
and angioplasty using the same balloon. One of the
concerns regarding this technology is that barotrauma
from the ﬂuid jet produced by the porous balloon might
stimulate intimal hyperplasia.25 There is also the potential
for nonhomogeneous drug delivery if the pores occlude.
Lastly, the drug may escape into the systemic circulation
if there is not good apposition of the balloon to the arterial
wall.25 A microporous balloon has been developed to
address the concern of barotrauma related to ﬂuid release
from the balloon. This consists of an inner porous balloon
surrounded by an outer membrane with narrower fenes-
trations that reduce the force of the solution as it is
released.26
Porous balloons have been used clinically, but only in
a few patients and not as part of large prospective trials.
Latif and Hennebry27 reported the use of a porous balloon
to treat in-stent restenosis in two patients with extensive
peripheral vascular disease. Paclitaxel was administered
after angioplasty using a Vascular Clearway irrigation
balloon, a porous balloon made by Atrium Medical (Hud-
son, NH), which is an FDA-approved device for thedelivery of thrombolytic agents.27 Drug delivery was
successful in both patients, with no evidence of restenosis
by angiography 4 months after the intervention.27 Atrium
has recently sponsored the Local Paclitaxel Delivery for
SFA Disease (IRRITAX) trial, a randomized, single-
center pilot study to evaluate this balloon in combination
with paclitaxel for the treatment SFA stenosis. Large and
randomized trials will be needed to fully validate long-
term outcomes with this technology.27
EXTRALUMINAL DRUG-DELIVERY DEVICES
Perivascular biomaterials. Although intraluminal
therapies for coronary and peripheral vascular disease have
become increasingly prevalent, thousands of open surgical
revascularizations are still being performed worldwide each
year with no available techniques to limit restenosis or intimal
hyperplasia in these patients. Interestingly, the opportunity
exists at the time of surgery to extraluminally apply a therapy
that can prevent the development of recurrent disease
(Table IV). Extraluminal application of a restenotic drug
has distinct advantages over intraluminal therapy. Drugs
applied extraluminally will saturate the arterial adventitia, and
it is well recognized that the adventitia contributes
Study type Pts, No.
Primary patency
rate, time
Rate of binary
restenosis, time TLR, time
Prospective, multicenter,
double blind, randomized
93 NR DES: 23% (2 months);
BMS: 21% (24 months)
DES: 6% (24 months);
BMS: 13% (24 months)
Prospective, multicenter,
nonrandomized, single arm,
open label
104 DES: 68% (12 months) NR DES: 0% (12 months)
Prospective, multicenter,
randomized, open label
474 DES: 83% (12 months);
PTA: 33% (12 months)
NR DES: 10% (12 months);
BMS: 18% (12 months)
Prospective, multicenter,
single blind, randomized
140 DES: 85% (12 months);
BMS: 54% (12 months)
DES: 17% (12 months);
BMS: 36% (12 months)
DES: 8% (12 months);
BMS: 35% (12 months)
Prospective, multicenter,
double blind, randomized
161 DES: 81% (12 months);
BMS 56% (12 months)
DES: 19% (12 months);
BMS: 44% (12 months)
DES: 10% (12 months);
BMS: 18% (12 months)
Prospective, multicenter,
randomized, open label
200 NR DES: 21% (12 months);
PTA: 45% (12 months)
DES: 10% (12 months);
PTA: 17% (12 months)
Prospective, nonrandomized,
single arm, open label
30 DES: 97% (8 months) NR NR
Prospective, multicenter,
randomized, open label
140 Primary outcome at 6 months NA NA
Prospective, multicenter,
single arm, open label
60 Primary outcome at 12 months NA NA
Prospective, multicenter,
single arm, open label
70 Primary outcome at 12 months NA NA
Prospective, multicenter,
single arm, open label
70 Primary outcome at 6 months,
12 months
NA NA
Table II. Continued.
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migration of myoﬁbroblasts into the neointima.28 Drugs
applied extraluminallywill alsodiffuse into themedia and into
the subintima and can prevent the production of subintimal
plaque. Lastly, the concentrations of drug that reach the
intima or the endothelial layer are markedly diminished,
lessening that chance that drug application will inhibit re-
endothelialization of the vessel lumen.
In multiple animal studies of restenosis, hydrogels have
been used to suspend drugs for adventitial delivery. Hydro-
gels are a composed of a network of hydrophilic polymer
chains that have a high content of water. They are biocom-
patible, and their permeability makes them ideal for drug
delivery. Innumerable studies in animals have used hydro-
gels to deliver drugs or molecular tools, or both, to prevent
intimal hyperplasia.29,30 In fact, hydrogels have become
a common research tool for the delivery of agents under
investigation as inhibitors of restenosis. Although results
in animals have been encouraging, one of the disadvantages
of traditional hydrogels is their rapid release of drug. Early-
generation hydrogels elute drugs in <3 days. It has become
increasingly clear that prolonged drug release may be
necessary to prevent recurrent disease associated withmost vascular reconstructions. This clinical and pharmaco-
logic limitation has led to the development of newer hydro-
gels with modiﬁcations (pH or temperature) that allow
controlled and sustained release of drug.
Another approach to periadventitial drug delivery is
the perivascular wrap. Kelly et al31 tested ethylene vinyl
acetate perivascular wraps loaded with paclitaxel in
a porcine model of arteriovenous graft stenosis. These
investigators found that the anastomoses treated at the
time of surgery with the paclitaxel-loaded polymer wraps
developed less luminal stenosis than untreated graft-to-
vein anastomoses (0.17% in the paclitaxel group vs
37.90% stenosis in the control group). Poly(ε-caprolactone)
(PCL) is a biocompatible and biodegradable polymer
that has also been used to deliver paclitaxel and rapamy-
cin to the vessel wall. PCL has been studied extensively
in vitro and in vivo, resulting in FDA approval of many
medical drug delivery devices composed of PCL. In
a mouse femoral artery injury model, investigators
placed PCL cuffs loaded with paclitaxel or rapamycin
or control cuffs around injured femoral arteries. At 3
weeks, paclitaxel and rapamycin-eluting PCL reduced
intimal thickening by 76% and 75%, respectively.
Table III. Trials evaluating drug-eluting balloons
Trial name/author
Vascular
territory Status Study period Drug; balloon Excipient/carrier
Montevergine
Registry
SFA Presented at
LINC 2012
Unknown Paclitaxel; unknown Unknown
Micari et al41 SFA/POP Published May 2008-Sept 2010 Paclitaxel; IN.PACT
Admiral
Freepac (urea)
PACIFIER SFA/POP Presented,
ongoing
Mar 2010-Dec 2012 Paclitaxel; IN.PACT
Paciﬁc
Freepac (urea)
THUNDER SFA/POP Published Jul 2004-Oct 2007 Paclitaxel; unknown Unknown
FEMPAC SFA/POP Published Apr 2004-Jul 2007 Paclitaxel; unknown Unknown
LEVANT I SFA/POP Presented Jun 2009-Dec 2011 Paclitaxel; Moxy Lutonix proprietary hydrophilic
nonpolymeric carrier
LEVANT II
(clinical trial)
SFA/POP Ongoing Jul 2011-Dec 2016 Paclitaxel; Moxy Lutonix proprietary hydrophilic
nonpolymeric carrier
Inpact SFA I SFA/POP Ongoing Sep 2010-Jul 2016 Paclitaxel; IN.PACT
Admiral
Freepac (urea)
Inpact SFA II SFA/POP Ongoing Mar 2012-Mar 2018 Paclitaxel; IN.PACT
Admiral
Freepac (urea)
Advance 18 PTX SFA/POP Unpublished Oct 2008-Dec 2013 Paclitaxel; Advance
18 PTX
None
DEBELLUM SFA/POP/
BTK
Presented at
LINC 2012
Unknown Paclitaxel; IN.PACT
Admiral & Amphirion
Freepac (urea)
Leipzig Registry,
Schmidt et al42
BTK Published Jan 2009-Feb 2010 Paclitaxel; IN.PACT
Amphirion
Freepac (urea)
DEBATE-BTK BTK Presented at
LINC 2012
Nov 2010-Nov 2012 Paclitaxel; IN.PACT
Amphirion
Freepac (urea)
Inpact DEEP BTK Ongoing Sep 2009-Dec 2015 Paclitaxel; IN.PACT
Amphirion
Freepac (urea)
PICCOLO BTK Unpublished Apr 2008-Apr 2011 Paclitaxel; Invatec
Amphirion
Unknown
BTK, Below the knee; DEB, drug-eluting balloon; DEBELLUM, Drug Eluting Balloon Evaluation for Lower Limb mUltilevel treatMent; LINC, Leipzig
Interventional Course; NA, not available; NR, not reported; PACIFIER, Paclitaxel Coated Balloons in Femoral Indication to Defeat Restenosis;
PICCOLO, Drug Coated Balloons for Prevention of Restenosis; POP, popliteal; PTA, percutaneous transluminal angioplasty; SFA, superﬁcial femoral
artery; THUNDER, Local Taxane with Short Exposure for Reduction of Restenosis in Distal Arteries; TLR, target lesion revascularization.
Advance PTX, Cook Medical, Bloomington, Ind.
Moxy, Moxy, New Hope, Minn.
IN.PACT Amphirion, Medtronic, Minneapolis, Minn.
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indeed local, with no adverse systemic effects.
Despite signiﬁcant success in animal models, this tech-
nology has been slow to enter human clinical trials. We
found only one company that is close to human trials. Ves-
selTek Biomedical (Chicago, Ill) is currently developing
a drug-eluting perivascular wrap (VTek-RA wrap) con-
structed from poly(diol citrate). Their wrap is designed
for local drug delivery and is biodegradable. This product
is currently in the FDA premarket approval stage.
Injection catheters. Injection catheters are intralumi-
nal devices that contain microneedles capable of delivering
drugs to the periadventitial space. Upon insufﬂation, the
microneedles pierce the vessel wall and release the drug
into and around the vessel’s adventitia. An obvious advan-
tage of this device is that a drug can be delivered to theouter vascular wall by a percutaneous intervention.
Therefore, the drug is not delivered directly to the
vessel lumen, consequently diminishing its effect on re-
endothelialization. Tian et al32 investigated the effect of
adventitial paclitaxel delivery to the porcine femoral artery
using a three-prong needle injection catheter. The inves-
tigators concluded that the injection catheter was an
effective method of drug delivery because the neointimal
area was reduced from 2.8 to 0.41 mm2 and restenosis was
reduced from 47% to 13%.32 Using the same animal model,
Gasper et al33 evaluated the delivery of nanoparticle
albumin-bound (nab)-rapamycin using a modiﬁed version
of the foregoing injection catheter containing one micro-
needle and found decreased intimal hyperplasia and nega-
tive remodeling. A disadvantage of injection catheters is the
potential for uneven distribution of the drug.34 Another
Randomization Pts, No. Late lumen loss, time TLR, time
Rate of binary restenosis,
time
Single arm, observational
registry
39 NR DEB: 7.9% (12 months) NR
Single arm, observational
registry
105 NR DEB: 7.6% (12 months) NR
Prospective, multicenter,
single blind, randomized
91 DEB: 0.01 mm
(6 months); PTA:
0.65 mm (6 months)
DEB: 7.1% (6 months);
PTA: 21.4% (6
months)
DEB: 8.6% (6 months);
PTA: 32.4% (6
months)
Prospective, multicenter,
double blind, randomized
154 DEB: 0.4 6 1.2 mm
(6 months); PTA: 1.7 6
1.8 mm (6 months)
DEB: 15% (24 months);
PTA: 52% (24
months)
DEB: 17% (6 months);
PTA: 44% (6 months)
Prospective, multicenter,
single blind, randomized
87 DEB: 0.5 6 1.1 mm
(6 months); PTA: 1.0 6
1.1 mm (6 months)
DEB: 13% (24 months);
PTA: 50% (24
months)
DEB: 19% (6 months);
PTA: 47% (6 months)
Prospective, multicenter,
single blind, randomized
101 DEB: 0.36 mm (6 months);
PTA: 1.08 mm (6 months)
DEB: 6% (6 months);
PTA: 21% (6 months)
NR
Prospective, multicenter,
single blind, randomized
w700 NA NA NA
Open label, randomized w150 NA NA NA
Single blind, randomized w450 NA NA NA
Open label, randomized w150 NA NA NA
Single center, randomized,
blinding unknown
50 (92 SFA/POP
lesions, 30
BTK lesions)
DEB: 0.5 6 1.4 mm
(6 months); PTA: 1.6 6
1.7 mm (6 months)
DEB: 8% (6 months);
PTA: 36% (6 months)
NR
Single arm, observational
registry
104 NR DEB: 17.3% (12
months)
DEB: 27.4% (3 months)
Single center, double blind
randomized
111 NR NR DEB: 29% (12 months);
PTA: 72% (12months)
Multicenter, double blind,
randomized
Unknown NA NA NA
Multicenter, double blind,
randomized
114 NA NA NA
Table III. Continued.
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administered in excessive doses to a localized area, with the
potential of aneurysm formation or rupture related to
extensive necrosis.
Mercator MedSystems (San Leandro, Calif) recently
introduced a microinfusion catheter with one injection
needle. This consists of a balloon-sheathed microneedle
that can be deployed by a low-pressure balloon. When
the desired injection site is reached, the balloon is
expanded, securing the system and allowing the sliding
microneedle to penetrate the vessel wall. The FDA has
given the Micro-Infusion Catheter 510(k) clearance. We
were unable to ﬁnd any published literature in which this
microinfusion catheter was used, although data recently
presented at the Society for Vascular Surgery Annual
Conference suggests this device is ready for clinical safetytrials. More recently, two injection catheters developed
by Bavaria Medizin Technologie GmbH (Germany) and
Binlab Inc (Webster, Tex) have been patented, but there
are no published data describing their efﬁcacy.SYSTEMIC DRUG ADMINISTRATION
Intravenous drug delivery. The FDA ﬁrst approved
paclitaxel in December 1992 for marketing under the
trade name Taxol (Bristol-Myers Squibb, Princeton,
NJ). This form of paclitaxel is given to patients intrave-
nously and contains ethanol and Cremophor EL (BASF
Aktiengesellschaft, Germany) to increase its solubility.
Unfortunately, these additives cause severe hypersensi-
tivity reactions that require patients be medicated with
corticosteroids and antihistamines before treatment.
Table IV. Extraluminal drug delivery devices
Extraluminal
devices Advantages Disadvantages Current status
Representative
publications
Author (year)
Injection
catheter
d Periadventitial drug release
through a percutaneous
approach
d High concentration of drug
can be delivered
d Uneven distribution of drug
(highest concentration of
drug at injection site)
Currently in preclinical
animal studies
Tian et al32 (2006)
Gasper et al33 (2011)
Perivascular
biomaterials
d Drug delivery applicable to
open surgical repair or
bypass
d Material may produce peri-
vascular inﬂammation
d Need for materials that
provide long-term drug
delivery
Currently in preclinical
animal studies
Moon et al43 (2004)
Kelly et al31 (2006)
Siow et al28 (2007)
Yau et al44 (2008)
Table V. Systemic administration
Systemic
administration Advantages Disadvantages Current status
Representative publications
Author (year)
Intravenous d Cost
d No need for antipla-
telet therapy
d No need for invasive
intervention
d Neutropenia, leuko-
penia, and alopecia
Currently in clinical trials
(100-300 patients)
Margolis et al45 (2006)
Chan et al11 (2011)
Deglau et al35 (2011)
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007, Abraxane; AbraxisBioScience, Los Angeles, Calif ) was
approved for the treatment of metastatic breast cancer.
This modiﬁcation signiﬁcantly improved the efﬁcacy and
safety proﬁle of paclitaxel. The absence of solvents abol-
ished the need for premedication. There have been several
clinical trials (Systemic Nanoparticle Paclitaxel (nab-pacli-
taxel) for In Stent Restenosis [SNAPIST]-I, -II, and -III)
to assess the efﬁcacy of nab-paclitaxel (Coroxane; Abraxis-
BioScience) in preventing restenosis after bare-metal stent-
ing of de novo coronary lesions. The complexity of this
treatment is that it produces neutropenia, leukopenia,
and alopecia, particularly in high doses, as detailed in
Table V. The second version of this trial, SNAPIST-II,
was a randomized comparison in 76 patients of one dose
(35 mg/m2) and one dose plus a repeat dose at 2 months
(35 mg/m2) of nab-paclitaxel. At 6 months, there was no
statistically signiﬁcant difference in rates of restenosis
between the two groups by angiography or ultrasound
assessment. SNAPIST-III, a randomized clinical trial
enrolling 122 patients, has recently been completed. This
study randomized patients to four groups using lower
doses of the nab-paclitaxel than in the previous two trials,
speciﬁcally 10, 22, 35, and 45 mg/m2. Results of this trial
are currently being analyzed.
Several other systemically administered pharmacothera-
peutic regimens have been effective in preventing restenosis
in animal models, but their success is yet to be translated tohuman trials, related to poor tolerance and a narrow ther-
apeutic range for these drugs.4,5
Targeted intravenous drug delivery. Another prom-
ising method of local drug delivery involves using systemic
treatment targeted to a speciﬁc tissue. These agents are
systemically administered, but ﬁnd their way to the injured
vessel after vascular intervention because of tissue-speciﬁc
tags. Deglau et al35 investigated a site-speciﬁc delivery
system using microspheres capable of carrying therapeutic
drugs composed of a reactive polyethylene glycol tagged
with avidin and a balloon that coats the injured artery with
biotin. The Remedy microporous balloon was used to
deliver biotin molecules to the surface of rabbit femoral
arteries after injury.35 Microspheres that were coated with
avidin, which has a high afﬁnity for biotin, were then
administered intravenously, and these microspheres
attached to the biotin on the arterial wall, locally releasing
the drug. This approach, using microspheres containing
a drug that inhibits restenosis, has the potential to locally
deliver a systemically injected antirestenotic agent.
Another method of targeted drug delivery through
systemic injection is by using microspheres that target
proteins that are speciﬁcally expressed or upregulated after
vascular injury. For example, investigators have created
microspheres or particles that directly target surface
markers that are exposed after vascular injury, including
E-selectin, P-selectin, intercellular adhesion molecule 1,
and vascular cell adhesion molecule 1.
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to speciﬁc proteins within the injured arterial wall. Chan
et al11 designed a nanoparticle with a lipid core-shell inter-
face between poly(lactide-co-glycolide)-glycolic acid and
polyethylene glycol polymers and peptides directed against
collagen IV. This nanoparticle, loaded with paclitaxel, was
designed to bind to collagen IV in the basal lamina of the
vessel wall, which is exposed after endothelial denudation
from mechanical injury.36 Safety studies have shown that
rats receiving targeted nanoparticles had no signs of
toxicity. In a rat carotid injury model, targeted nanoparticle
delivery of paclitaxel given as a two-dose infusion on days
0 and 5 after injury prevented arterial stenosis, as evidenced
by a 50% reduction in the intima-to-media ratio when
compared with the control. The site-speciﬁc delivery of
this nanoparticle could provide a safe and effective treat-
ment of restenosis that does not require a direct intralumi-
nal or extraluminal intervention. However, clinical trials are
needed to test the safety and efﬁcacy of these innovative
techniques.
CONCLUSIONS
The forgoing reveals an explosion of interest in the
development of preventative treatments for restenosis.
The spectrum ranges from DESs, which are used in routine
clinical practice, to DEBs that are now entering the clinical
arena, to targeted nanoparticles that are just being evalu-
ated in animals.
A search of current projects funded by the National
Institutes of Health, using the keywords “drug delivery”
and “restenosis,” reveals a multitude of interesting en-
deavors. Most of the proposals we identiﬁed were focused
on systemic delivery of locally targeted drug carriers, such
as liposomes, microspheres, or nanoparticles, with the
goal of altering their biochemical properties to maximize
efﬁciency of drug delivery to the arterial wall. Similarly,
over the past 2 years, >65 new patents have been issued
for approaches to local drug delivery that are focused on
preventing restenosis.
With this incredible amount of innovation, it seems
likely that great strides will be made in the near future in
the prevention of restenosis. The central theme that will
likely produce this success is targeted or local and sustained
delivery of high concentrations of an inhibiting compound
or compounds. In this review we have attempted to
comprehensively describe the approaches to local drug
delivery that are currently in use or under investigation.
This is a rapidly moving ﬁeld, and by the time this review
is published, new trials will likely have come to completion
and new innovations will have been developed.
Although there are many promising venues for drug
delivery, DESs and DEBs currently have the full attention
of industry; these are the technologies that will likely be
assimilated into practice over the next few months to years.
Nevertheless, many potentially less expensive and more
effective technologies are under development. There is
little doubt that over the next decade, the methods usedto prevent restenosis will continue to evolve. Restenosis is
a devastating process that affects millions of individuals
each year. Our review of this ﬁeld suggests that the future
is bright and a solution will soon be at hand.
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